Lasokun

Ranolazine, the active ingredient in Lasokun, is an antianginal agent presented as an oral dosage form for oral use. It is indicated for the treatment of chronic stable angina in adults, helping to reduce the frequency of angina attacks and improve exercise tolerance. It works by targeting cardiac myocyte ion channels to improve myocardial perfusion.

GNH USA supplies Lasokun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Ranolazine is used in the management of angina pectoris and related ischemic heart conditions.

- Chronic stable angina: reduces frequency of angina episodes and improves exercise capacity. - Exercise‑induced angina: alleviates chest pain during physical activity by enhancing myocardial blood flow. - Refractory angina: provides symptom relief when conventional therapies are insufficient.

Ranolazine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to arrhythmias. - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Severe hypotension: marked drop in blood pressure. - Hepatic injury: abnormal liver function tests or hepatitis.

When prescribing Lasokun, clinicians should consider several precautionary measures to ensure patient safety.

- Assess renal function: adjust therapy in patients with impaired clearance. - Monitor ECG: watch for QT interval prolongation. - Avoid in severe hepatic impairment: contraindicated due to limited metabolism. - Use caution in heart failure: monitor for worsening symptoms. - Store at room temperature: keep in original container, protect from moisture.

Ranolazine can interact with other medicines, requiring attention to avoid clinically significant effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ranolazine levels. - Drugs that prolong QT interval (e.g., sotalol, quinidine): risk of additive QT prolongation. - Digoxin: co‑administration can raise digoxin concentrations.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): monitor plasma levels. - Other antianginal agents (e.g., nitrates, beta‑blockers): observe for additive hypotensive effects. - Diuretics: watch electrolyte balance, especially potassium.